ClinicalTrials.gg
RecruitingNCT07322432CONQUERUpdated Jan 7, 2026

The CONQUER Trial - Cessation Of Nicotine, QUitting With E-cigarette Reduction

A Phase 2 interventional study of VapeAway filter system in Addiction Nicotine, sponsored by VapeAway. Recruiting at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by VapeAway · Phase 2, Interventional, and Other

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 799 studies in Tobacco Use Disorder with a site in United States — 75 open to participants now, 91 under way, 5 of them phase 3. Tobacco Use Disorder · United States.

Planned enrollment
408th of 736
70 · median 84
Started
2025
with 22 others
Phase 2
130 of 799
9 open now
Primary completion
2026-12
later than 14 of 90 live
Registered
784th of 799
by date

Among the 799 studies in Tobacco Use Disorder with a site in United States, this one is the 408th largest by planned enrollment of the 736 interventional ones that give a count, is one of 23 that started in 2025, is one of 130 in phase 2, reaches primary completion later than 14 of the 90 other live ones, and was the 784th registered.

Tobacco Use Disorder

1,028 studies on the registry are indexed under Tobacco Use Disorder; 128 are open to participants now.

Browse Tobacco Use Disorder studies →

Open to participants now

75 of the 799 studies in Tobacco Use Disorder with a site in United States are open now. Recruiting first, the newest first:

69 more — sign in →

All 75 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 95 Tobacco Use Disorder studies recruiting now, 42 (44%) set no upper age limit and 50 (53%) stop at 75 or younger; 6 take children under 18; 37 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 799 studies in Tobacco Use Disorder with a site in United States, or all of them as a file.
02

Study summary

This clinical trial evaluates the VapeAway system, a novel, multi-modal intervention designed to address the multifaceted nature of vaping addiction. VapeAway combines progressive nicotine tapering via proprietary filters, behavioral substitution with a sensory device (Fix Bar), and structured digital support. The purpose of this research is to evaluate the efficacy and safety of the investigational VapeAway system, a multi-component behavioral and nicotine-reduction intervention, for promoting cessation of nicotine-containing e-cigarette use in motivated adults. The primary objective is to determine if the VapeAway program can achieve a Continuous Abstinence Rate (CAR) of at least 25% at 30 days post-intervention completion, a rate which will be statistically compared to the historical spontaneous cessation rate of approximately 7%. Secondary objectives include assessing reductions in biochemical nicotine exposure (cotinine), vaping frequency, withdrawal symptoms, and electronic cigarette dependence, as well as characterizing the safety and tolerability profile of the intervention.

Participants will be asked to follow the VapeAway system (filters, Fix Bar and timeout periods) as prescribed by the protocol for about 42 days. During this time, participants should keep track of vaping sessions throughout the trial.

Read the detailed description

This is a Phase II, single-arm, open-label, multi-center, interventional trial designed to assess the efficacy and safety of the VapeAway system for vaping cessation.

The study will enroll approximately 70 adult participants who are daily users of nicotine-containing e-cigarettes and are motivated to quit.

All enrolled participants will receive the active VapeAway intervention, which consists of a 42-day (±21 days) core program utilizing progressive nicotine tapering filters, a behavioral substitution device (Fix Bar), and a digital support system. The total study duration per participant will be approximately 90 days. The primary efficacy endpoint, the Continuous Abstinence Rate (CAR) at 30 days post-intervention completion, will be statistically compared to a predefined historical control spontaneous cessation rate of 7%.

The study will enroll adult males and females, aged 21 years and older, who are daily or near-daily users of nicotine-containing e-cigarettes for at least 3 months, have a saliva cotinine level ≥10 ng/mL, and score ≥4 on the Penn State Electronic Cigarette Dependence Index (PSECDI). Participants must be highly motivated to quit, as confirmed by standardized assessments (Likert scale, Motivation To Stop Scale, and the Preparation stage of the Transtheoretical Model).

The study includes several componenets:

  1. Nicotine Tapering Filters: Participants will self-administer by attaching a new, study-supplied filter to their personal e-cigarette device each morning. Filters are used for all vaping sessions throughout the day and discarded after 24 hours. Participants will progress through the three filter levels (25%, 50%, 75% reduction) at scheduled intervals as follows:

    • Level 1 Filter (Days 1-14 ±7 days): Reduces nicotine delivery by 25% relative to baseline vaping device.
    • Level 2 Filter (Days 14-28 ±7 days): Reduces nicotine delivery by 50%.
    • Level 3 Filter (Days 28-42 ±7 days): Reduces nicotine delivery by 75%. Fix Bar: The Fix Bar is a behavioral substitution tool used in conjunction with nicotine tapering to replace the act of vaping. It can be used whenever the participant is vaping less than their baseline level, and it increases in use proportionally across each level.
    • Each Fix Bar contains three toothpicks and is refilled daily.
    • There are three distinct Fix Bars, one for each level of the program.
    • Participants will be assessed for their baseline vaping use calculated as hours per/day and will be instructed to increase Fix Bar usage (as a vaping replacement) for each timeout level, with target time replacements as follows:

    Level 1 (Days 1-14 ±7 days):

    • Week 1: Replace 15-20% of vaping time with Fix Bar
    • Week 2: Replace 30-35% of vaping time with Fix Bar

    Level 2 (Days 14-28 ±7 days):

    • Week 3: Replace 45-50% of vaping time with Fix Bar
    • Week 4: Replace 60--65% of vaping time with Fix Bar

    Level 3 (Days 28-42 ±7 days):

    • Week 5: Replace 80-85% of vaping time with Fix Bar
    • Week 6: Replace 95-100% of vaping time with Fix Bar
  2. Use of the Fix Bar to replace vaping as oral fixation is optional however, the timeout periods are mandatory and will be tracked weekly. All participants will receive comprehensive training on the correct use of all system components at the Day 1 visit. Adherence will be monitored through weekly logs and reviewed at each study visit. Biochemical verification (saliva cotinine) will be performed at scheduled timepoints.
  3. Digital Support System: Participant Support Messaging Protocol. As part of the intervention strategy for this study, all enrolled participants will receive ongoing motivational and supportive communication throughout the trial period and for a follow-up duration of up to 3 months post-intervention completion. The purpose of these communications is to enhance engagement, provide encouragement, and support participants in their efforts to reduce or cease vaping.
  4. Text Message Support: Participants will receive up to five pre-written support text messages per week. These messages will be:

    • Designed to be motivational, encouraging, and engaging.
    • Focused on reinforcing positive behavior change, promoting well-being, and addressing common challenges in vaping cessation.
    • Tailored where possible to the participant's stage in the cessation journey.
  5. Daily Text Messages: Separate from the support messages, participants will receive daily text messages reminding them of the number of timeout hours they are required to do for the day.

Upon completion of the intervention, participants will be followed for 30 days and a saliva cotinine test will be performed at the end of the follow-up period to confirm cessation.

03

Conditions studied

  • Addiction Nicotine

Keywords

  • Vaping
  • Vaping Addiction
  • Vaping Cessation
  • Vape
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: Adults aged 21 years and older
  • Current Vaping Behavior: Daily or near-daily use (≥5 days/week or at least 20 days per month) of nicotine-containing e-cigarettes for at least the past 3 months.
  • Motivation and desire to quit as determined by all of the following three assessment tools:

    • Score of 4 or 5 on all 5-point Likert-type scale questions (see appendix)
    • Score of 6 or 7 on Motivation To Stop Scale (MTSS) (see appendix)
    • Participants must be classified in the Preparation stage of the Transtheoretical Model of behavior change (see appendix)
  • Saliva Cotinine level ≥ 10 ng/ml
  • Penn State Electronic Cigarette Dependence Index (PSECDI) of at least 4 and above
  • Willingness to participate in the study and all study requirements
  • Willingness to not use any other nicotine-containing products for the duration of the study
  • Ability to attend visits and provide

Exclusion criteria

Exclusion Criteria:

  • Mental Health Concerns with a score above the following thresholds:

    • PHQ-2 score ≥ 2 (see appendix)
    • GAD-2 score ≥ 2 (see appendix)
  • Use of Other Tobacco or Nicotine Products:

    • Use of any nicotine products except for vaping, including combustible tobacco (e.g., cigarettes) or other non-e-cigarette nicotine delivery systems within the past 30-days
  • Current Substance or alcohol Use Disorder:

    • Self-reported or medically diagnosed substance use disorder (excluding nicotine), unless in sustained remission (>12 months).
    • Illicit drug use in the past 60 days
    • Screening positive for alcohol use disorder in past year
  • Medical :

    • Any serious medical condition or medication that would contraindicate participation in a behavioral cessation trial (to be defined and assessed by study physician or PI).
    • Pregnant or breastfeeding
    • Symptomatic cardiovascular disease
    • Participation in another smoking/vaping cessation trial
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Intervention Arm

    Participants with a vaping addiction that use the VapeAway system to help vaping cessation

    Device: VapeAway filter system

Interventions

  • DeviceVapeAway filter system

    A multi-component, drug-free program for vaping cessation. The system integrates three core elements: nicotine tapering filters, fix bar behavioral substitution tool, digital support system.

06

What researchers measure

Primary outcomes

  1. Vaping Cessation

    To determine the prevalence of vaping abstinence (quit rates) with the VapeAway system at 30 days after completion of the program (intervention period) verified by self-reporting and biochemical testing

    Time frame: up to 90 days

Secondary outcomes

  1. Filter Compliance

    Percent of time the subject vaped with use of filter

    Time frame: Up to 63 days

07

Study locations

1 of 1 sites recruiting
  • Prime Infusion
    New York, New York 10128, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 41 phase 2 interventional studies under Tobacco Use Disorder, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 1, 2026
First posted
Jan 7, 2026
StartActual
Dec 24, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07322432
Lead sponsor
VapeAway
Responsible party
Sponsor
First posted
Jan 7, 2026
Start date
Dec 24, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 7, 2026

Study contacts

Sarah Clinical Trial Manager, PhD
Contact
trial.vapeaway@gmail.com
2017548404
Mendel Goldfinger, MD
principal investigator · VapeAway

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion